{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:06:06Z","timestamp":1782169566251,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2017YFC0907904"],"award-info":[{"award-number":["2017YFC0907904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Efficacy and safety of PARPi\/anti-PD-1 in advanced solid tumors were retrospectively analyzed. The efficacy measures included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This retrospective study included data from 40 patients. The ORR was 27.5% (95% CI, 13.0\u201342.0%), with a DCR of 85.0% (95% CI, 73.4\u201396.6%). Except four patients in first-line treatment (three with PR and one with SD), the ORR of \u2265second-line treatment, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) was 22.2%, 23.1% and 28.6%, and the DCR was 83.3%, 84.6% and 71.4%, separately. The median PFS of all patients, \u2265second-line treatment, NSCLC and SCLC was 4.6\u00a0m, 4.2\u00a0m, 4.5\u00a0m and 3.7\u00a0m. The median OS was 9.4\u00a0m, 11.4\u00a0m, 12.7\u00a0m and 5.4\u00a0m, respectively. Multivariable analysis revealed that BRCA1\/2 mutation was positively correlated with ORR (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.008), and LDH\u2265250U\/L was negatively correlated with lowered DCR (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.018), while lymphocyte number, ECOG and LDH significantly influenced both PFS and OS. We found that the possible resistant mechanisms were sarcomatous degeneration and secondary mutation, including BRCA2 truncation mutation, A2M, JAK1,T790M, KEAP1 and mTOR mutation. 37.5% patients had \u2265grade 3 adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PARPi\/anti-PD-1 is an effective and tolerable method for patients with advanced solid tumors, and BRCA1\/2 is a potential biomarker.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-021-02852-4","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T13:04:49Z","timestamp":1616159089000},"page":"2971-2980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-5741","authenticated-orcid":false,"given":"Zhaozhen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhefeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5692","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"issue":"3","key":"2852_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2852_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"6330","key":"2852_CR3","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A (2017) PARP inhibitors: Synthetic lethality in the clinic. Science 355(6330):1152\u20131158. https:\/\/doi.org\/10.1126\/science.aam7344","journal-title":"Science"},{"issue":"21","key":"2852_CR4","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753","journal-title":"Cancer Res"},{"issue":"24","key":"2852_CR5","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","volume":"78","author":"RA Stewart","year":"2018","unstructured":"Stewart RA, Pilie PG, Yap TA (2018) Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res 78(24):6717\u20136725. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2652","journal-title":"Cancer Res"},{"issue":"1","key":"2852_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J (2019) Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific Reports 9(1):1853. https:\/\/doi.org\/10.1038\/s41598-019-38534-6","journal-title":"Scientific Reports"},{"issue":"4","key":"2852_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","volume":"463","author":"J Huang","year":"2015","unstructured":"Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS (2015) The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer. Biochem Biophys Res Commun 463(4):551\u2013556. https:\/\/doi.org\/10.1016\/j.bbrc.2015.05.083","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"2852_CR8","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res Official J Am Assoc Cancer Res 23(14):3711\u20133720. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3215","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res"},{"key":"2852_CR9","doi-asserted-by":"crossref","unstructured":"Robillard L, Nguyen M, Loehr A, Orsulic S, Kristeleit RS, Lin K, Raponi M, Harding TC, Simmons AD, Robillard L (2017) Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model. In: Aacr Meeting.","DOI":"10.1158\/1538-7445.AM2017-3650"},{"issue":"2","key":"2852_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G (2019) PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 79(2):311\u2013319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003","journal-title":"Cancer Res"},{"issue":"1","key":"2852_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40425-018-0445-4","volume":"6","author":"KE Fenerty","year":"2018","unstructured":"Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW (2018) Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J Immunother Cancer 6(1):133. https:\/\/doi.org\/10.1186\/s40425-018-0445-4","journal-title":"J Immunother Cancer"},{"key":"2852_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Farkkila A, D\u2019Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P (2019) Single-arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1048","journal-title":"JAMA Oncol"},{"key":"2852_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML (2019) Open-label clinical trial of Niraparib combined with Pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029","journal-title":"JAMA Oncol"},{"key":"2852_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.026","author":"A Thomas","year":"2019","unstructured":"Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, Chen Y, Velcheti V, Yin F, Szabo E, Pommier Y, Steinberg SM, Trepel JB, Raffeld M, Young HA, Khan J, Hewitt S, Lee JM (2019) Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. J Thoracic Oncol Official Publ Int Assoc Study Lung Cancer. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.026","journal-title":"J Thoracic Oncol Official Publ Int Assoc Study Lung Cancer"},{"key":"2852_CR15","doi-asserted-by":"publisher","unstructured":"Karzai F, Madan RA, Owens H, Couvillon A, Hankin A, Williams M, Bilusic M, Cordes LM, Trepel JB, Killian K, Meltzer PS, Gulley JL, Lee J-m, Dahut WL (2018) A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. J Clinical Oncol 36 (6_suppl):163-163. https:\/\/doi.org\/10.1200\/JCO.2018.36.6_suppl.163","DOI":"10.1200\/JCO.2018.36.6_suppl.163"},{"issue":"4","key":"2852_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imm.12099","volume":"139","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Bennici E, Novelli F, Pioli C (2013) Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 139(4):428\u2013437. https:\/\/doi.org\/10.1111\/imm.12099","journal-title":"Immunology"},{"key":"2852_CR17","doi-asserted-by":"publisher","unstructured":"Reck M, Vicente D, Ciuleanu T, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo N, Juan-Vidal O, Cheng Y (2018) Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Ann Oncol Official J Europ Soc Med Oncol 29 (suppl_10):39-43. https:\/\/doi.org\/10.1093\/annonc\/mdy511.004","DOI":"10.1093\/annonc\/mdy511.004"},{"issue":"12","key":"2852_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-018-0593-2","volume":"19","author":"C Garcia","year":"2018","unstructured":"Garcia C, Ring KL (2018) The role of PD-1 checkpoint inhibition in gynecologic malignancies. Curr Treat Options Oncol 19(12):70. https:\/\/doi.org\/10.1007\/s11864-018-0593-2","journal-title":"Curr Treat Options Oncol"},{"key":"2852_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"WD Yu","year":"2019","unstructured":"Yu WD, Sun G, Li J, Xu J, Wang X (2019) Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett 452:66\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.048","journal-title":"Cancer Lett"},{"issue":"1","key":"2852_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-017-3825-0","volume":"18","author":"T O'Donnell","year":"2018","unstructured":"O\u2019Donnell T, Christie EL, Ahuja A, Buros J, Aksoy BA, Bowtell DDL, Snyder A, Hammerbacher J (2018) Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer 18(1):87. https:\/\/doi.org\/10.1186\/s12885-017-3825-0","journal-title":"BMC Cancer"},{"key":"2852_CR21","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1200\/JCO.2020.38.15_suppl.9614","volume":"38","author":"Y He","year":"2020","unstructured":"He Y, Li X, Dang S, Liu G, Song L, Zhu B, Zhou C (2020) Effect of genomic and transcriptional alterations in first-line chemotherapy on subsequent immunotherapy in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 38:9614\u20139614. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9614","journal-title":"J Clin Oncol"},{"key":"2852_CR22","doi-asserted-by":"publisher","unstructured":"Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O\u2019Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL, Group AS (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma. Cancer Discovery 7(9):984\u2013998. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0419","DOI":"10.1158\/2159-8290.CD-17-0419"},{"issue":"9","key":"2852_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. New Engl J Med 375(9):819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"New Engl J Med"},{"issue":"12","key":"2852_CR24","doi-asserted-by":"publisher","first-page":"e0189514","DOI":"10.1371\/journal.pone.0189514","volume":"12","author":"S Kurz","year":"2017","unstructured":"Kurz S, Thieme R, Amberg R, Groth M, Jahnke HG, Pieroh P, Horn LC, Kolb M, Huse K, Platzer M, Volke D, Dehghani F, Buzdin A, Engel K, Robitzki A, Hoffmann R, Gockel I, Birkenmeier G (2017) The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat. PloS one 12(12):e0189514. https:\/\/doi.org\/10.1371\/journal.pone.0189514","journal-title":"PloS one"},{"issue":"13","key":"2852_CR25","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M (2018) Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res Official J Am Assoc Cancer Res 24(13):3108\u20133118. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2961","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res"},{"issue":"2","key":"2852_CR26","first-page":"612","volume":"12","author":"H Tao","year":"2020","unstructured":"Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y (2020) Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation. Am J Translational Res 12(2):612\u2013617","journal-title":"Am J Translational Res"},{"issue":"7","key":"2852_CR27","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5(7):1008\u20131019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02852-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T13:08:46Z","timestamp":1631020126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02852-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2852"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02852-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the national research committee and with the Helsinki Declaration. This study was approved by the ethics committee of Chinese PLA General Hospital (approval number: S2019-184-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the patients were informed of the possible treatment-related adverse events by doctors and signed informed consent before using PARP inhibitor and PD-1\/PD-L1 inhibitor. Written informed consent was obtained before blood samples and tissue specimens were collected. This study does not contain any individual person\u2019s information of patients, and all patients have consented to participate in this study and publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}